ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Cenegenics Improves Operational Efficiency with Domo

Domo (Nasdaq: DOMO) announced today that Cenegenics, a leader in the performance health technology industry, now uses its cloud-native data and analytics platform to improve patient care through real-time insights, accessible data and optimized inventory.

Cenegenics helps patients achieve their peak cognitive, physical and metabolic health by leveraging data from various biomarkers. Just as patients use Cenegenics to enhance their health, Cenegenics needed more real-time visibility into its business performance. Information was siloed in disconnected systems, meaning analysts spent weeks manually gathering and analyzing data. With Domo, Cenegenics now has complete, real-time data and insights into operations at individual clinics, delivering the visibility the business needs to compete in a quickly-evolving space.

“Before we implemented Domo at Cenegenics, it could take months to get access to important data we needed such as revenue and patient retention,” said Roxana Boboescu, Director of Business Intelligence at Cenegenics. “Our focus wasn’t just about getting the right data, but it was about getting it at a speed that allowed us to quickly recognize factors in our business that weren't working and make timely changes that help give us a competitive edge.”

Cenegenics also utilizes Domo to monitor and improve the patient experience. For example, the company can see patient responses to communications across text, phone calls and email, and then tailors message efforts via the channels that drive better engagement. The company can also analyze which products and services are most widely used across physicians and locations. Through a better understanding of how each physician uses specific products, Cenegenics can order exactly what it needs when it needs it, allocating resources accordingly and ultimately reducing its inventory costs.

The company uses Domo to measure each clinic’s progress across core KPIs, giving executives, physicians and coaches the ability to compare performance over time periods and locations, and equipping them with all the resources needed to make improvements. In its first year using Domo, Cenegenics has brought its health-optimizing technology to a broader audience, increasing its client count by 16%, signups by 11% and revenue by 10%.

“Cenegenics demonstrates how improved data experiences can translate to tangible, real-world benefits,” said Mark Maughan, chief analytics officer and SVP of customer success, Domo. “When you have the ability to provide real-time updates and make data accessible, not only do organizations see a positive business impact, but their customers feel it too. With Cenegenics, that means there are people who are performing better.”

To learn more about how innovative organizations like Cenegenics are using Domo to put data to work for everyone, visit www.domo.com/customers.

About Domo

Domo puts data to work for everyone so they can multiply their impact on the business. Our cloud-native data experience platform goes beyond traditional business intelligence and analytics, making data visible and actionable with user-friendly dashboards and apps. Underpinned by AI, data science and a secure data foundation that connects with existing cloud and legacy systems, Domo helps companies optimize critical business processes at scale and in record time to spark the bold curiosity that powers exponential business results.

For more information, visit www.domo.com. You can also follow Domo on LinkedIn, X and Facebook.

Domo is a registered trademark of Domo, Inc.

Cenegenics demonstrates how improved data experiences can translate to tangible, real-world benefits. - Mark Maughan, chief analytics officer and SVP of customer success, Domo

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.